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Objective: To evaluate broth microdilution, disk diffusion, Etest and Vitek Systems for susceptibility testing of 
enterococci. 
Methods: Susceptibility testing of a panel of 149 enterococci (99 vancomycin-resistant) strains, using the study 
methods, was performed and the results compared. 
Results: For vancornycin susceptibility testing, categorical agreement of disk diffusion, Etest and Vitek with the 
reference broth microdilution test was > 95%. For aminoglycoside and ampicillin testing, categorical agreement between 
Etest and Vitek was 98 to  100%. 
Conclusions: Disk diffusion, Etest and Vitek have acceptable performance for detection of vancomycin resistance of 
Van A and Van B phenotypes among enterococci. 
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Enterococci are now the third most common cause of 
nosocomial bloodstream infection and the second most 
common cause of nosocomial wound and urinary tract 
infection [I ,2]. Therapy of enterococcal infection has 
become increasingly difficult as resistance to ampicillin, 
glycopeptides (vancomycin, teicoplanin) and the 
synergic activity of aminoglycosides combined with cell 
wall-active agents have emerged [1,3-91. Approxi- 
mately 8 to 10% of nosocomial enterococcal isolates in 
the United States are now vancomycin-intermediate or 
-resistant, and epidemiological data indicate progressive 
spread from the initial focus in the Northeastern areas 
of the US as well as continued spontaneous mutation 
There are three vancomycin resistance phenotypes: 
(1) Van A (acquired inducible high-level resistance to 
vancomycin and teicoplanin); (2) Van B (acquired 
inducible resistance to vanconiycin without resistance 
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to teicoplanin); and (3) Van C (intrinsic resistance to 
low levels of glycopeptides characteristic of Enterococcus 
casseliflavus, Enterococcus gallinarum and Enterococcus 
javescem)  [12]. These three vanconiycin resistance 
phenotypes are associated with the specific genes van 
A, van B and van C, respectively, and the genotypes can 
be detected by either probe hybridization or poly- 
merase chain reaction (PCR) amplification using 
specific primers [10,12]. 
Given the widespread and rapidly evolving resist- 
ance patterns, empirical therapy of enterococcal in- 
fection is no longer tenable, and it is essential that 
clinical laboratories be able to rapidly and reliably 
detect antimicrobial-resistant isolate5. Previous studies 
have documented the inadequacy of automated suscep- 
tibility products, some broth microdilution (BMD) 
systems and the standardized disk diffusion test inter- 
pretive criteria [7,13-171. In response to these problems, 
the National Committee for Clinical Laboratory 
Standards (NCCLS) modified the disk diffusion test 
interpretive criteria (susceptible at  2 17 mni, resistant 
at 1 1 4  mm) [18], and the manufacturers of the Vitek 
(bioM6rieux Vitek, Inc., Hazelwood, MO) suscept- 
ibility test system have recently updated the software 
used to interpret the susceptibility of enterococci. 
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To evaluate contemporary methods (1 995) for suscept- 
ibility testing of enterococci, we performed vanconiycin 
susceptibility tests with 149 enterococcal isolates, using 
reference UMD, disk diffusion, Vitek and Etest (AB 
Biodisk, Solna, Sweden) methodologies. As Vitek does 
not include testing for susceptibility to teicoplanin, we 
additionally compared the Etest results with those of 
the reference BMD method for this newer glyco- 
peptide. For ampicillin, gentamicin and streptomycin, 
which have important continuing roles in the therapy 
of enterococcal infection, we compared the Etest 
method (previously validated for these drugs) with the 
Vitek system [19-221. 
A panel of 149 enterococci (88 Entcroioccus faciium, 
49 Entrvococciis facialis, seven E. gallinarum, three 15. 
casselijlavus, one Entcroioccus durans and one unspeciated 
EUteF'cJCoiiu-C strain) from 65 hospitals in 35 states was 
selected for testing [111 (Table 1). These strains possessed 
a variety of susceptibility patterns to the penicillins, 
aniinoglycosides and glycopeptides. The organism 
collection included 99 vanconiycin-resistant strains, of 
which 55 had previously determined Van A phenotypes 
(34 confirmed genotypically), 34 Van B phenotypes (24 
confirmed genotypically) and 10 (E .  gallinarum and 
E. casselijuvus) Van C phenotypes [ l l ] .  In addition, 
analysis of restriction enzynie digests of genoniic DNA 
by pulsed field gel electrophoresis of the Van A strains 
avoided the use of identical or copy strains due to intra- 
or interhospital transmission [ I  11. The remaining 50 
isolates were susceptible to vanconiycin and each was 
isolated froni a different hospital to avoid geographically 
imposed strain bias. P-lactamase-producing strains were 
not included in this panel of enterococci [41. 
Teicoplanin was provided by Marion Merrell Ilow 
Pharmaceuticals (Kansas City, MO) and vanconiycin by 
Eli Lilly CC; Co. (Indianapolis, IN). 
Both BMII and disk diffusion susceptibility tests 
were performed and interpreted in accordance with the 
recoiiimcridations of the NCCLS 123,241, and the Etest 
and Vitek susceptibility test according to the nianu- 
facturers' instructions. In brief, a volume of trypticase 
soy broth was inoculated to the turbidity of a 0.5 
McFarland standard. This suspension was used to 
inoculate the surface of a Mueller-Hinton agar plate 
provided by Remel (Lenexa, KS), and was then diluted 
and inoculated, using an automated instrument (Dyna- 
tec Laboratories, Chantilly, VA), into cation-adjusted 
Mueller-Hinton BMD trays obtained froni Prepared 
Media Laboratories (Tualatin, OK). After an appro- 
priate drying time, the agar plates had a 30-pg 
vancomycin disk (Becton Dickinson Microbiology 
Systems, Cockeysville, MD) and Etest strips applied to 
its surface. All tests were incubated at 35' C in ambient 
air for 24 h. The recoininended suspension of organism 
was inoculated into the GPS-TA Vitek susceptibility 
card and results were computed using Vitek system 
software (version 8.4). For purposes of comparison, 
Etest results were rounded up to the next two-fold 
dilution step if the result was not at  the usually applied 
log2 dilution from unity (1 pg/mL). When the Vitek 
result was off-scale (for example, 2 32 pg/mL for 
vancomycin), this was considered to be essentially in 
agreement with a value of 2 32 pg/niL resulting froni 
a true niinimurii inhibitory concentration (MIC) 
method (such as BMII or Etest). Quality control was 
perforined concurrently using E. fuccalis American 
Type Culture Center (ATCC) 2921 2, Esrhcviiliia roli 
ATCC 25922, and Stapliyloioicirs aurens ATCC 25923 
and 29213. 
The agreement of vancomycin MIC results (k I to 
2 log2 dilution steps) and susceptibility categorization 
obtained with disk diffusion, Etest and Vitek coinpared 
with the reference BMII test result are summarized in 
Table 2. Teicoplanin MICs and susceptibility categori- 
zation using Etest and BMD are also summarized in 
Table 2. Quantitative agreement f 1 log. dilution 
step was observed at > 90% for both commercial vanco- 
niycin MIC tests conipared with the reference BMI) 
method. Absolute categorical agreement was > 95'X and 
all errors were minor. For vanconiycin susceptibility 
testing by Etest compared with the reference BM1) 
system, there were seven minor errors: six strains 
susceptible by BM1) were interniediate by Etest; and 
one strain intermediate by BMII was resistant by 
Etest. For vanconiycin susceptibility testing by Vitek 
compared with BMD, there were five minor errors: 
Table 1 Viiiconiycin niiniinurii iiihibitory concentrations (MICs) measured by the broth rnicrod~lution tect for the 149 
Errtrr.onicn~s pccies strains in the study 
Vancomycin MlCs 
spccic\ ( I f  testcd) < ( I 2 5  0.5 1 2 4 8 16 > I 6  
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four strains susceptible by BMD were intermediate by 
Vitek; and one strain intermediate by BMD was 
resistant by Vitek. For vancomycin susceptibility testing 
by disk diffusion compared with BMD, there were six 
minor errors: three strains susceptible by BMD were 
intermediate by disk diffusion; two strains intermediate 
by BMD were susceptible by disk diffusion; and one 
strain resistant by BMD was intermediate by disk 
diffusion. For teicoplanin susceptibility testing by Etest 
compared with BMD, there were 11 minor errors: 
eight strains intermediate by BMD were resistant by 
Etest; and three strains resistant by BMD were inter- 
mediate by Etest. All 10 strains (seven E.  gallinariurn and 
three E. casselijlavus) with intrinsic low-level glyco- 
peptide resistance (Van C phenotype) were categorized 
as susceptible to vancomycin by the reference BMD 
and Vitek methods. Using the Etest and disk diffusion 
susceptibility test, three of these 10 isolates were cate- 
gorized as intermediate. 
For teicoplanin Etest results, the quantitative (k 1 
log2 dilution) agreement was slightly reduced (82.6%), 
but higher (97.9%) at the k 2 log2 dilution comparison. 
O f  55 Van A strains (teicoplanin-resistant by agar 
dilution) [21], 13 (23.6%) were categorized as inter- 
mediate to teicoplanin (MIC 16 pg/mL) by BMD, 
but only eight (14.5%) were intermediate by Etest. 
For the majority of these strains, genotyping had been 
performed or confirmed the presence of the van A 
gene in all strains examined. All Van C strains were 
interpreted as susceptible to teicoplanin by both in- 
vitro methods. 
Table 2 Agreement of Etest, Vitek and disk diffusion 
susceptibility tests with reference broth microdilution test 
results for vancomycin and teicoplanin against 149 
enterococci 
Vancomycin 
Intermethod Disk Teicoplanin 
agreement Etest Vitek diffusion Etest 
i 1 log2 dilution 94.6% 98.0% - 82.6% 
i 2 log2 dilution 98.6% 99.3% - 97.9% 
Categorical 95.3% 96.6% 96.0% 92.6% 
Table 3 summarizes the degree of agreement 
between Vitek and Etest susceptibility test results for 
ampicillin, gentamicin, streptomycin and vancomycin. 
Absolute categorical agreement was 2 98.7% for all 
four cited antimicrobial agents. For vancomycin sus- 
ceptibility testing, there was a single discrepancy of a 
strain susceptible by Vitek that was intermediate by 
Etest. For ampicillin susceptibility testing, one strain 
resistant by Vitek (MIC > 16 pg/mL) was susceptible 
by Etest (MIC 8 pg/mL) and one strain susceptible by 
Vitek (MIC 8 pg/mL) was resistant by Etest (MIC > 
256 pg/mL). For gentamicin, one strain was resistant 
by Vitek and susceptible by Etest and agar dilution; 
another strain was susceptible by Etest, but resistant by 
Vitek and by agar dilution. 
Options for therapy of enterococcal infection have 
become limited as resistance to ampicillin, penicillin, 
gentamicin, streptomycin and glycopeptides becomes 
more widespread [1,3,5,7-111. To optimize the use of 
these established agents, it is essential that laboratories 
be able to identify drug-resistant strains and to define 
precisely the resistance phenotypes. Streptomycin may 
be useful in the therapy of some gentamicin-resistant 
isolates, and teicoplanin (where available) may be used 
for a subset of vancomycin-resistant organism infections 
(Van B phenotype). 
Among the most widely used methods for sus- 
ceptibility testing are the standardized disk diffusion test 
[23], and the commercially available Etest and Vitek 
system. It is essential to define the degree of confidence 
with which laboratory technicians and clinicians can 
utilize the results generated by these methods or 
products. Because of the limitations of earlier inter- 
pretive criteria for disk diffusion and some commercial 
susceptibility tests systems [7,13-171, an agar dilution 
reference screening test, using 6 pg/mL of vancomycin, 
has been developed [25 1. The performance of the agar 
dilution plate is excellent as a reference procedure; 
however, it is limited in that it addresses only vanco- 
mycin resistance and that it may not be practical for 
many laboratories to use a separate test method (agar 
ddution) for a specific organism/antimicrobial combi- 
nation. 
In this study, we have evaluated the utility of the 
most recent modifications of the disk diffusion, Etest 
and Vitek system methods for detection of vancomycin 
and other drug resistance in enterococci. All three 
methods produced an absolute categorical agreement 
of > 95% compared with the reference BMD test [24]. 
The favorable performance of Vitek in this evaluation 
Table 3 Intermethod agreement of minimum inhibitory 
concentration determinations using Etest and Vitek for 
vancornycin, ampicillin, gentamicin and streptomycin 
Antimicrobial agent 
Intermethod 
agreement Vancomycin Anipicillin Gentamicin Streptomycin 
? 1 log2 
* 2 log2 
dilution 88.6% 91.9% NA NA 
dilutions 100.0% 96.6% NA NA 
Categorical 99.3% 98.7% 98.7% 100.0% 
NA = not applicable 
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contrasts with the major error rate of 10.3% reported 
by Tenover and colleagues [26]. This apparently contra- 
dictory experience has a number of possible explana- 
tions. In the earlier report [26], the generation ofVitek 
software used was not specified, but niay have differed 
from that used in our study. Furthermore, the com- 
position and size of the collection of strains studied 
is substantially different. The earlier study involved 
50 strains from a reference collection, of which 20%) 
( n  = 10) and 40% ( n  = 20) were Van A and Van B, 
respectively. The major error rate of 10.3% reflects 
problenis with only three Van B strains: one strain failed 
to grow in the Vitek card; and two strains had true wide 
discrepancies from the reference BMU method results. 
Our study comprised a larger collection of recent 
clinical isolates which differed significantly in coni- 
position - 36.9% (55 strains) and 22.8% (34 strains) 
were Van A or Van B strains, respectively. 
None of the methods studied appears to be 
satisfactory for detection of low-level vancomycin 
resistance of the Van C phenotype. Thus, the correct 
identification of the enterococcal species harboring this 
intrinsic resistance or the application of iiiolecular 
techniques niay become the basis of recognition of this 
resistance. In addition, we have demonstrated the 
accuracy of the teicoplanin Etest strip. Although 
teicoplanin is not approved for clinical use in many 
nations, it has been widely used in Europe and is also 
available on a ‘compassionate-use’ basis for therapy of 
infection with v m  B resistant enterococci. 
Among strains with defined vaii A resistance 
genotype, 85.5% were categorized as teicoplanin- 
resistant and 14.5% as intermediate by Etest. This result 
compares favorably with the reference BMU test, 
which categorized 23.6% of these truly resistant strains 
as intermediate. These minor errors are, however, of 
limited practical significance as there is a distinct 
separation between the MIC values for genotypically 
susceptible strains (maximum MIC 2 pg/niL) and those 
for v m  A strains (MIC 2 16 pg/mL). The frequency of 
this minor error, and the clear separation between 
susceptible and resistant organism populations suggest 
that the breakpoints for teicoplanin against enterococci 
could be reduced by 1 log2 dilution. Our  investigation 
also validated the most recent software (version 8.4) of 
the Vitek system for detection of ampicillin and high- 
level aminoglycoside resistance in comparison to the 
previously approved Etest strip. 
Our results confirm that, at  present, three widely 
available susceptibility testing methods (disk diffusion, 
Etest and Vitek) are acceptable for detection of 
glycopeptide resistance of the common Van A and 
Van B phenotypes in enterococci. Furthermore, for 
other important therapeutic antimicrobials (penicillins, 
aminoglycosides), the Vitek results are comparable to 
the reference-quality Etest method. 
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